Aug. 14 at 4:51 PM
$GERN According to Perplexity, this is what's happened since Geron's August 5th earnings report: "Wedbush reiterated its Buy rating on August 5 with a
$6.00 target.
TD Cowen also issued a Buy recommendation around the results, though the available report does not disclose a target change.
H.C. Wainwright maintained a Hold rating and cut its 2026 EPS forecast to a
$0.05 loss from a
$0.02 loss, but the source does not report a price-target revision.
So, I would not treat this as confirmation that any biotech analyst raised or cut a price target after August 5. The clearest reported target was Wedbush’s unchanged
$6.00, and overall published consensus was about
$4.00"
